First of all, this is not a political blog. Second, I am certain that someone will still think it is. Third, in this case, I do not care as I am an ex-FDAer that truly believes in the Agency and wants to see it succeed. I was rooting for Scott’s nomination for many reasons, […]
After yesterday’s post (here), final numbers for February are out and, while good, it was not the jump we have hoped for. The total approvals for February, 61, were very close to the 60 reported on the New and Generic Drug Approvals site for the month. This is the lowest discrepancy seen in many months. […]
Almost every health-related headline today mentions costs. Whether it be cost of health insurance, cost of hospital stays, doctor’s charges, and (of course) cost of drugs. While there are some shockers out there for drug costs, most are in line with expectations. One of the big problems is that even moderately priced drugs are most […]
Irritation has been building between the Office of Generic Drugs (OGD) and industry over the use of the terms backlog vs. workload, particularly over the last few months. At the recent Annual Meeting of the Association for Accessible Medicines (AAM), formerly the Generic Pharmaceutical Association (GPhA), the semantics pot almost boiled over. So why the […]
